FELTON, California, April 11, 2018 /PRNewswire/ --
The global Diabetic Retinopathy Market was valued atUSD 5,934.1 million in 2014 and is expected to reach USD 10.11 billion by 2022, with a CAGR of 6.8%. Diabetes is a constant disorder linked with defects in the discharge of insulin from the
Diabetic Retinopathy is generally classified into either proliferative retinopathy or non-proliferative DR. Cure for DR is dependent relatively on the phase of the ailment and is focused on trying to stop or slow the succession of the disease. Currently three types of cure exist for Diabetic Retinopathy which is anti-VEGF drugs into the eye or injection of corticosteroids, laser surgery and vitrectomy. Advancements in knowledge have led to the modernization of new goods that offer rapid and secure methods to cure diabetic retinopathy. Augmented use of vitrectomy in the healing of retinal impassiveness is one such trend.
The increase in diabetes tolerant, great inhabitants of baby boomers, and shifting lifestyle in budding countries are some of the leading factors expected to drive diabetic retinopathy market over the forecast period. Additionally, the amplified health awareness and growing disposable income in budding countries have enlarged the superior healthcare services, affordability; which in turns is driving the industry of diabetic retinopathy. The growing awareness in the direction of the cure of diabetic retinopathy and progression of patient monitoring by the electronic medical record are some of current market trend in the diabetic retinopathy industry. The treatment process of diabetic retinopathy depends on a variety of stages of diabetic retinopathy. The increasing market for diabetic retinopathy can be accredited to increasing geriatric population size.
Browse 80 page research report with TOC on "Global Diabetic Retinopathy Market" at: https://www.millioninsights.com/industry-reports/diabetic-retinopathy-market
Additionally, up gradation of healthcare infrastructure in the length of the increasing demand for early on detection systems are some of the soaring impact drivers for the DR industry. Also, the medical pipeline for Diabetic Retinopathy seems full of assurance by lots of drug beneath umbrella specially directing towards diabetic retinopathy amongst the diabetic patients. Moreover, a shortage of skilled ophthalmologist coupled with deprived primary infrastructure and shortage in a requirement of insurance facilities are expected to pose the challenge for the growth of global diabetic retinopathy industry.
On the basis disease type, the global diabetic retinopathy industry can be broadly categorized as proliferative retinopathy and non-proliferative diabetic retinopathy. On the basis of the different treatment techniques, the global diabetic retinopathy industry can be generally categorized as corticosteroids injection, Laser surgery, and anti-VEGF drugs. On the basis of different drug use in the worldwide diabetic retinopathy industry, the market can be bifurcated as Anti-Angiogenic, ocriplasmin, BI-30089, Squalamine Lactate, Proteoglycan, OC-10X, Lycium, ATL-1103 and STP-601.On the basis of a geographical region, the market can be segregated into Asia Pacific, North America, Europe and Rest of world. North America is expected to be the major market for diabetic retinopathy over the forecast period. The industry supremacy of North America is accredited to the soaring obesity rates and huge diabetic patients in this area. Furthermore, the helpful government proposal is also expected to be one of the important drivers of the industry in this area over the forecast period.
Europe is expected to be the second major market of diabetic retinopathy over the forecast period owing to the huge inhabitants of baby boomers in Europe is the most dominating growth factor for the diabetic retinopathy industry in this region over the forecast period. Asia Pacific is expected to demonstrate the highest expansion over the forecast period. The worthwhile augmentation of the diabetic retinopathy industry in Asia Pacific is accredited to the presence of a huge number of diabetic patients in China and India. Furthermore, increasing health consciousness coupled with growing expenditure on healthcare services is also propelling the diabetic retinopathy industry in this area. Beneath Rest of the World, sector Brazil is the biggest opportunity of diabetic retinopathy.
Some of the key players present in the market are Abbott Laboratories Inc, Hoffmann-La Roche Ltd, Bayer AG, Bayer AG, Novartis AG, Ampio Pharmaceuticals Inc, Alimera Science Inc, Regeneron Pharmaceutical Inc, and Pfizer Inc. Strategic acquisitions, new product launches, collaborations, agreements, mergers & acquisitions and joint ventures are some of the main things that are being done by the key players present in the market.
Browse reports of similar category available with Million Insights:
Global Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2012 - 2022)
Global Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2012 - 2022)
Intraocular steroid injection
Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2012 - 2022)
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
About Million Insights:
Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place, that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.
Contact: Ryan Manuel Research Support Specialist, USA Million Insights Phone: +1-408-610-2300 Toll Free: 1-866-831-4085 Email: firstname.lastname@example.org
SOURCE Million Insights
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All